Cardiff Oncology Inc
Research Cardiff Oncology Inc (CRDF) on Bullrun: market cap USD 69.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRDF
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 69.87M
- Financial periodQ1 2026
- RevenueUSD 525.00K
- Net income-USD 12.35M
- Free cash flow-USD 12.29M
Valuation Snapshot
latest market cap is USD 69.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 593.00K | -USD 45.85K | -USD 37.97M | n/a | -0.69 | USD 17.47M | USD 832.00K | USD 45.39M |
| FY2024 | USD 683.00K | -USD 45.43K | -USD 37.77M | n/a | -0.95 | USD 51.47M | USD 1.52M | USD 82.95M |
| FY2023 | USD 488.00K | -USD 41.44K | -USD 31.47M | n/a | -0.93 | USD 21.66M | USD 2.15M | USD 69.74M |
| FY2022 | USD 386.00K | -USD 38.70M | -USD 34.83M | n/a | -0.89 | USD 16.35M | n/a | USD 106.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 69.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 191.94M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 288.72M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 66.12M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 62.55M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 252.20M | n/a | n/a | n/a |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cardiff Oncology Inc's market cap?
Cardiff Oncology Inc's market capitalization is USD 69.87M.
What does Cardiff Oncology Inc do?
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.